Mise à jour du calendrier vaccinal après allogreffe de cellules souches hématopoïétiques : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC).
Allogeneic haematopoietic stem cell transplantation; Allogreffe de cellules souches hématopoïétiques; Vaccination; Humans; Societies, Medical; France; Bone Marrow Transplantation; Hematopoietic Stem Cell Transplantation; Hematology; Oncology; Radiology, Nuclear Medicine and Imaging; Cancer Research; General Medicine
Abstract :
[en] During immune reconstitution following allogeneic haematopoietic stem cell transplantation (allo-HSCT), (re)vaccination of allo-HSCT recipients is recommended. Herein, we propose an update of practical recommendations regarding vaccination of allo-HSCT recipients. These recommendations, based on data from the literature, national and international guidelines and the consensus of the participants when no formally proven data are available, were elaborated during the workshop of practice harmonization organized by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) in Lille in September 2022.
Disciplines :
Hematology
Author, co-author :
Conrad, Anne ; Hospices civils de Lyon, hôpital de la Croix-Rousse, service des maladies infectieuses et tropicales, 103, grande rue de la Croix-Rousse, 69004 Lyon, France. Electronic address: anne.conrad@chu-lyon.fr
Beguin, Yves ; Université de Liège - ULiège > Département des sciences cliniques
Guenounou, Sarah; CHU de Toulouse, Institut universitaire du cancer de Toulouse, oncopole, service d'hématologie, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France
Le Bourgeois, Amandine; CHU de Nantes, service d'hématologie, 1, place Alexis-Ricordeau, 44000 Nantes, France
Ménard, Anne-Lise; Centre Henri-Becquerel, département d'hématologie clinique, rue d'Amiens, 76038 Rouen, France
Rialland, Fanny; CHU de Nantes, HME, 7, quai Moncousu, 44000 Nantes, France
Layal, Sharrouf; American University of Beirut Medical Center (AUBMC), division oncologie-hématologie, département de médecine interne, Beyrouth, Liban
Mamez, Anne-Claire; University of Geneva, Geneva University Hospitals, Department of Oncology, Division of Hematology, Geneva, Suisse
Yakoub-Agha, Ibrahim; CHU de Lille, université de Lille, LIRIC, Inserm U995, 59000 Lille, France
El Cheikh, Jean; American University of Beirut Medical Center (AUBMC), division oncology-hematology BMT program, département de médecine interne, Beyrouth, Liban
Language :
French
Title :
Mise à jour du calendrier vaccinal après allogreffe de cellules souches hématopoïétiques : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC).
Alternative titles :
[en] Vaccination of allogeneic haematopoietic stem cell transplant recipients: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
la SFGM-TC remercie les partenaires industriels pour leur soutien financier qui ont permis la réussite de cette treizième édition des ateliers d'harmonisation des pratiques : ACCORD HEALTHCARE, INCYTE, JAZZ Pharmaceuticals, MEDAC, MSD, SANOFI et VERTEX.
Rubio, M.-T., Charbonnier, A., de Berranger, E., Gandemer, V., Magro, L., Maury, S., et al. [Vaccination post hematopoietic stem cell transplantation: which vaccines and when and, how to vaccinate? An SFGM-TC report]. Pathol Biol (Paris) 61 (2013), 139–143, 10.1016/j.patbio.2013.07.004.
HCSP. Vaccination des personnes immunodéprimées ou aspléniques. Recommandations actualisées. 2014, Haut Conseil de la Santé Publique, Paris.
Cordonnier, C., Einarsdottir, S., Cesaro, S., Di Blasi, R., Mikulska, M., Rieger, C., et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis 19 (2019), e200–e212, 10.1016/S1473-3099(18)30600-5.
Tipton, R., Yakoub-Agha, I., [How we harmonize HSCT clinical practices among the SFGM-TC centers]. Bull Cancer 103 (2016), S193–S197, 10.1016/j.bulcan.2016.09.006.
CDC. ACIP timing and spacing guidelines for immunization. 2022, CDC [ https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html (accessed December 21, 2022)].
Carreras, E., Dufour, C., Mohty, M., Kröger, N., (eds.) The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies, 7th ed., 2019, Springer, Cham (CH).
Garcia Garrido, H.M., Haggenburg, S., Schoordijk, M.C.E., Meijer, E., Tanck, M.W.T., Hazenberg, M.D., et al. Immunogenicity of a 5-dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation. Am J Hematol 97 (2022), 592–602, 10.1002/ajh.26493.
Cordonnier, C., Ljungman, P., Juergens, C., Maertens, J., Selleslag, D., Sundaraiyer, V., et al. Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥ 2 years: an open-label study. Clin Infect Dis 61 (2015), 313–323, 10.1093/cid/civ287.
Kobayashi, M., Proposed updates to clinical guidance on pneumococcal vaccine use among adults. 2022, National Center for Immunization & Respiratory Diseases [ https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-10-19-20/04-pneumococcal-kobayashi-508.pdf (accessed December 21, 2022)].
Lewalle, P., Pochon, C., Michallet, M., Turlure, P., Brissot, E., Paillard, C., et al. [Prophylaxis of infections post-allogeneic transplantation: guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 106:1S (2019), S23–S34, 10.1016/j.bulcan.2018.08.017.
WHO, Hepatitis B vaccines: WHO position paper – July 2017. Wkly Epidemiol Rec, 92, 2017, 27 [https://www.who.int/publications-detail-redirect/WER9227 (accessed December 21, 2022)].
Piekarska, A., Wisniewski, P., Lewandowski, K., Gil, L., Trzonkowski, P., Bieniaszewska, M., et al. Immune status against hepatitis B in patients after allogeneic hematopoietic cell transplantation-factors affecting early and long-lasting maintenance of protective anti-HBs titers. Front Immunol, 11, 2020, 586523, 10.3389/fimmu.2020.586523.
CDC. COVID-19 vaccination guidance for people who are moderately or severely immunocompromised. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. https://www.cdc.gov/vaccines/covid-19/images/COVID19-vaccination-schedule-immunocompromised.png [accessed December 21, 2022].
EBMT. COVID-19 vaccines. Version 8, January 3, 2022. https://www.ebmt.org/sites/default/files/2022-01/COVID%20vaccines%20version%208.3%20-%202022-01-03.pdf [accessed December 21, 2022].
ASH. ASH-ASTCT COVID-19 vaccination for HCT and CAR T cell recipients: frequently asked questions (Version 5.0; last updated March 22, 2022). https://www.hematology.org:443/covid-19/ash-astct-covid-19-vaccination-for-hct-and-car-t-cell-recipients [accessed December 21, 2022].
Haute Autorité de santé. Stratégie vaccinale de rappel contre la COVID-19 (validée par le Collège le 19 septembre 2022, mise à jour le 8 décembre 2022). https://www.has-sante.fr/upload/docs/application/pdf/2022-12/strategie_vaccinale_de_rappel_contre_la_covid-19-recommandation.pdf [accessed December 21, 2022].
Meites, E, Szilagyi, PG, Chesson, HW, Unger, ER, Romero, JR, Markowitz, LE, Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 68:32 (2019), 698–702, 10.15585/mmwr.mm6832a3.
Laws, H.-J., Baumann, U., Bogdan, C., Burchard, G., Christopeit, M., Hecht, J., et al. Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (III) Impfen bei hämatologischen und onkologischen Erkrankungen (antineoplastische Therapie, Stammzelltransplantation), Organtransplantation und Asplenie. Bundesgesundheitsbl 63 (2020), 588–644, 10.1007/s00103-020-03123-w.
Ljungman, P., Lewensohn-Fuchs, I., Hammarström, V., Aschan, J., Brandt, L., Bolme, P., et al. Long-term immunity to measles, mumps, and rubella after allogeneic bone marrow transplantation. Blood 84 (1994), 657–663.
Groeneweg, L., Loeffen, Y.G.T., Versluys, A.B., Wolfs, T.F.W., Safety and efficacy of early vaccination with live attenuated measles vaccine for hematopoietic stem cell transplant recipients and solid organ transplant recipients. Vaccine 39 (2021), 3338–3345, 10.1016/j.vaccine.2021.04.049.
Pergam, S.A., Englund, J.A., Kamboj, M., Gans, H.A., Young J-AH, Hill, J.A., et al. Preventing measles in immunosuppressed cancer and hematopoietic cell transplantation patients: a position statement by the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant 25 (2019), e321–e330, 10.1016/j.bbmt.2019.07.034.
Griffin, D.E., The immune response in measles: virus control, clearance and protective immunity. Viruses, 8, 2016, E282, 10.3390/v8100282.
Kakoulidou, M., Ingelman-Sundberg, H., Johansson, E., Cagigi, A., Farouk, S.E., Nilsson, A., et al. Kinetics of antibody and memory B cell responses after MMR immunization in children and young adults. Vaccine 31 (2013), 711–717, 10.1016/j.vaccine.2012.11.031.
Chun, J.Y., Kim, K., Lee, M.K., Kang, C.K., Koh, Y., Shin, D.-Y., et al. Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients. BMC Infect Dis 21 (2021), 1–7, 10.1186/s12879-021-05806-4.
Aoki, T., Koh, K., Kawano, Y., Mori, M., Arakawa, Y., Kato, M., et al. Safety of live attenuated high-titer Varicella-Zoster virus vaccine in pediatric allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 22 (2016), 771–775, 10.1016/j.bbmt.2015.12.025.
Issa, N.C., Marty, F.M., Leblebjian, H., Galar, A., Shea, M.M., Antin, J.H., et al. Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 20 (2014), 285–287, 10.1016/j.bbmt.2013.11.013.
Baumrin, E., Izaguirre, N.E., Bausk, B., Feeley, M.M., Bay, C.P., Yang, Q., et al. Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantation. Blood Adv 5 (2021), 1585–1593, 10.1182/bloodadvances.2020003749.
